{"DataElement":{"publicId":"3916137","version":"1","preferredName":"Therapeutic Procedure 5-HT3 Receptor Antagonist Administered Type","preferredDefinition":"The type related to the administration of a 5-HT3 receptor antagonist. In medicine, a substance that stops the action or effect of another substance. A protein complex that plays a role in neurotransmitter-gated ion transport. It is a pentamer that binds serotonin and is comprised of either five 5-hydroxytryptamine receptor 3A subunits or a combination of four 5-hydroxytryptamine receptor 3A molecules with one of the alternative subunits, 5-hydroxytryptamine receptor 3B, 3C, 3D or 3E.","longName":"FIVEHT3TYPE","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"3916132","version":"1","preferredName":"Therapeutic Procedure 5-HT3 Receptor Antagonist Administered","preferredDefinition":"Information related to the administration of a 5-HT3 receptor antagonist. In medicine, a substance that stops the action or effect of another substance. A protein complex that plays a role in neurotransmitter-gated ion transport. It is a pentamer that binds serotonin and is comprised of either five 5-hydroxytryptamine receptor 3A subunits or a combination of four 5-hydroxytryptamine receptor 3A molecules with one of the alternative subunits, 5-hydroxytryptamine receptor 3B, 3C, 3D or 3E.","longName":"FIVEHT3","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3916130","version":"1","preferredName":"5-HT3 Receptor Antagonist Administered","preferredDefinition":"A protein complex that plays a role in neurotransmitter-gated ion transport. It is a pentamer that binds serotonin and is comprised of either five 5-hydroxytryptamine receptor 3A subunits or a combination of four 5-hydroxytryptamine receptor 3A molecules with one of the alternative subunits, 5-hydroxytryptamine receptor 3B, 3C, 3D or 3E.:In medicine, a substance that stops the action or effect of another substance. For example, a drug that blocks the stimulating effect of estrogen on a tumor cell is called an estrogen receptor antagonist.:The act of having given something (e.g., a medication or test).","longName":"C105979:C94373:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"5-HT3 Receptor","conceptCode":"C105979","definition":"A protein complex that plays a role in neurotransmitter-gated ion transport. It is a pentamer that binds serotonin and is comprised of either five 5-hydroxytryptamine receptor 3A subunits or a combination of four 5-hydroxytryptamine receptor 3A molecules with one of the alternative subunits, 5-hydroxytryptamine receptor 3B, 3C, 3D or 3E.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Antagonist","conceptCode":"C94373","definition":"In medicine, a substance that stops the action or effect of another substance. For example, a drug that blocks the stimulating effect of estrogen on a tumor cell is called an estrogen receptor antagonist.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E84FDE31-8032-3FE9-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E84FDE31-8043-3FE9-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3916133","version":"1","preferredName":"5-HT3 Receptor Antagonist Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"FIVEHT3TYPE","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Granisetron","valueDescription":"Granisetron","ValueMeaning":{"publicId":"3916134","version":"1","preferredName":"Granisetron","longName":"3916134","preferredDefinition":"Granisetron","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E850A5A1-CC8F-3806-E040-BB89AD437C38","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E850A5A1-CCA8-3806-E040-BB89AD437C38","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","deletedIndicator":"No"},{"value":"Ondasetron","valueDescription":"Ondasetron","ValueMeaning":{"publicId":"3916135","version":"1","preferredName":"Ondasetron","longName":"3916135","preferredDefinition":"Ondasetron","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E850A5A1-CCB2-3806-E040-BB89AD437C38","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E850A5A1-CCCB-3806-E040-BB89AD437C38","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","deletedIndicator":"No"},{"value":"Palonosetron","valueDescription":"Palonosetron","ValueMeaning":{"publicId":"3916136","version":"1","preferredName":"Palonosetron","longName":"3916136","preferredDefinition":"Palonosetron","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E850A5A1-CCD5-3806-E040-BB89AD437C38","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E850A5A1-CCEE-3806-E040-BB89AD437C38","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E850A5A1-CC7B-3806-E040-BB89AD437C38","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"ZIEGLERK","dateModified":"2013-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"FIVEHT3TYPE","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"5-HT3 receptor antagonist","type":"Preferred Question Text","description":"5-HT3 receptor antagonist","url":null,"context":"Alliance"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E84FDE31-8084-3FE9-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}